Wall Street Analyst Upgrade Global Blood Therapeutics Inc. [GBT]. What else is Wall St. saying

Global Blood Therapeutics Inc. [NASDAQ: GBT] gained 0.43% on the last trading session, reaching $67.04 price per share at the time. The company report on August 8, 2022 that Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion.

Potential to address the full spectrum of critical needs in the underserved sickle cell community.

Global Blood Therapeutics Inc. represents 65.59 million in outstanding shares, while the company has a total market value of $4.51 billion with the latest information. GBT stock price has been found in the range of $66.68 to $67.28.

If compared to the average trading volume of 2.64M shares, GBT reached a trading volume of 5347002 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Global Blood Therapeutics Inc. [GBT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GBT shares is $66.63 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GBT stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Canaccord Genuity have made an estimate for Global Blood Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 08, 2022. The new note on the price target was released on August 08, 2022, representing the official price target for Global Blood Therapeutics Inc. stock. Previously, the target price had yet another drop from $138 to $71, while Wedbush kept a Outperform rating on GBT stock.

The Average True Range (ATR) for Global Blood Therapeutics Inc. is set at 3.00, with the Price to Sales ratio for GBT stock in the period of the last 12 months amounting to 19.20. The Price to Book ratio for the last quarter was 37.24, with the Price to Cash per share for the same quarter was set at 7.69.

Trading performance analysis for GBT stock

Global Blood Therapeutics Inc. [GBT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.66. With this latest performance, GBT shares gained by 86.27% in over the last four-week period, additionally plugging by 117.66% over the last 6 months – not to mention a rise of 142.02% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GBT stock in for the last two-week period is set at 90.19, with the RSI for the last a single of trading hit 93.40, and the three-weeks RSI is set at 86.54 for Global Blood Therapeutics Inc. [GBT]. The present Moving Average for the last 50 days of trading for this stock 36.04, while it was recorded at 66.76 for the last single week of trading, and 31.91 for the last 200 days.

Global Blood Therapeutics Inc. [GBT]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Global Blood Therapeutics Inc. [GBT] shares currently have an operating margin of -147.72 and a Gross Margin at +93.87. Global Blood Therapeutics Inc.’s Net Margin is presently recorded at -155.63.

Return on Equity for this stock declined to -98.96, with Return on Assets sitting at -36.45.

Global Blood Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.20 and a Current Ratio set at 6.90.

Global Blood Therapeutics Inc. [GBT]: An earnings per share (EPS) analysis

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GBT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Global Blood Therapeutics Inc. go to 37.00%.

An analysis of insider ownership at Global Blood Therapeutics Inc. [GBT]

There are presently around $4,794 million, in the hands of institutional investors. The top three institutional holders of GBT stocks are: VANGUARD GROUP INC with ownership of 6,019,431, which is approximately -0.08% of the company’s market cap and around 1.90% of the total institutional ownership; BLACKROCK INC., holding 4,772,391 shares of the stock with an approximate value of $319.94 million in GBT stocks shares; and JANUS HENDERSON GROUP PLC, currently with $300.22 million in GBT stock with ownership of nearly -20.078% of the company’s market capitalization.

Positions in Global Blood Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 107 institutional holders increased their position in Global Blood Therapeutics Inc. [NASDAQ:GBT] by around 12,865,637 shares. Additionally, 103 investors decreased positions by around 11,761,091 shares, while 23 investors held positions by with 46,887,433 shares. The mentioned changes placed institutional holdings at 71,514,161 shares, according to the latest SEC report filing. GBT stock had 27 new institutional investments in for a total of 2,956,412 shares, while 34 institutional investors sold positions of 2,102,046 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here